Klinik für
Gefäß- und Thoraxchirurgie


Klinische Studien / Forschung

CaBaMet
Phase II Studie zur Behandlung mit Cabazitaxel von Patienten mit rezidivierten oder progredienten Hirnmetastasen eines Mammakarzinoms oder Lungenkarzinoms

LuCa BiO Registerstudie
Registerstudie zum biologischen Erkrankungsprofil und klinischem Verlauf bei Bronchialkarzinomen: die LuCa-Biology and Outcome-Studie (BiO)

Lux Lung 7
A randomised Phase IIb Trial of afatinib versus gefitinib as first-line treatment of patients with EGFR mutation positive advanced adenocarcinoma of the lung

B7391003 “BEVA”
A phase 3 randomized, double blind study of PF-06439535 plus PACLITAXEL-CARBOPLATIN and BEVACIZUMAB plus PACLITAXEL-CARBOPLATIN for the first-line treatment of patients with advanced non-squamous non-small cellung cancer 

PACIFIC
A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy

MORAb-009-201
A Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of Amatuximab in combination with Pemetrexed and Cisplatin in Subjects with unresectable Malignant Pleural Mesotheliom

CC-486-NSCLC-001
A Phase 2 multicenter, randomized, placebo controlled, double-blind study to assess the safety and efficacy of CC-486 (oral Azazidine) in combination with pembrolizumab (MK-3475) versus pembrolizumab plus placebo in subjects with previously treated locally advanced or metastatic NSCLC

PEARLS
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)

STIMULI
A randomized open-label phase II trial of consolidation ipilimumab in limited-stage SCLC after chemo-radiotherapy

GO29537
Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, anti-PD-L1 Antibody) in Combination with Carboplatin + Nab-Paclitaxel for Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

RIVA
Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism

FORCE
Fostering efficacy of anti – PD-1–treatment: Nivolumab plus radiotherapy in advanced NSCLC

CINC280B2201
A phase Ib/II, open-label, multicenter trial with oral cMET inhibitor INC280 alone and in combination with erlotinib versus platinum/pemetrexed in adult patients with EGFR mutated, cMET-amplified, locally advanced/metastatic nonsmall cell lung cancer (NSCLC) with acquired resistance to prior EGFR tyrosine kinase inhibitor (EGFR TKI)